ANDA 78364, held by Chartwell Rx. Desloratadine.
As of Nov 16, 2026, ANDA 78364 (Desloratadine), held by Chartwell Rx, was first approved by FDA on Dec 3, 2010, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 3, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desloratadine5MG · tablet;oral | Desloratadine | Discontinued |
| Oct 22, 2019 | Supplement 10Labeling · Standard review | Approved | None posted |
| Feb 13, 2015 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jan 9, 2014 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 3, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters